NBTX · Nasdaq, OTC · CIK 0001760854

Nanobiotix S.A.

Nanobiotix S.A.’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 26, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of EUR 32.6M and net income of -EUR 24.0M, according to its XBRL data on EDGAR. Its EDGAR record lists 0 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
EUR 32.6M
Net income, FY2025
-EUR 24.0M
Form 4 filings on record, past 12 months
0

Company overview

Legal name (as filed)
Nanobiotix S.A.
Tickers
NBTX, NNBXF
SEC Central Index Key (CIK)
0001760854
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
PARIS, France
State or country of incorporation
France
Fiscal year ends
December 31
SEC filer category
Accelerated filer
Position in SEC ticker list
#2182 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Nanobiotix S.A.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in EUR; the fiscal year is named for the calendar year in which it ends.

Revenue
EUR 2.6MFY2021EUR 4.8MFY2022EUR 36.2MFY2023-EUR 7.2MFY2024EUR 32.6MFY2025
Net income
-EUR 47.0MFY2021-EUR 57.0MFY2022-EUR 39.7MFY2023-EUR 68.1MFY2024-EUR 24.0MFY2025
NBTX annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
RevenueEUR 2.6MEUR 4.8MEUR 36.2M-EUR 7.2MEUR 32.6M
Net income-EUR 47.0M-EUR 57.0M-EUR 39.7M-EUR 68.1M-EUR 24.0M
Diluted EPS-EUR 1.35-EUR 1.64-EUR 1.08-EUR 1.44-EUR 0.50
Total assetsEUR 101.8MEUR 59.8MEUR 93.9MEUR 67.4MEUR 67.8M
Cash and equivalentsEUR 83.9MEUR 38.6MEUR 75.3MEUR 5.3MEUR 810.0K

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = Cash. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

NBTX latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 31, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 26, 20266-KReport of a foreign private issuer· period Oct 24, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Nanobiotix S.A., by form type:

6-K ×31FWP ×3SCHEDULE 13G/A ×2424B5 ×2S-8 ×120-F ×1
NBTX recent filings
FiledFormWhat it isOriginal
Oct 26, 20266-KReport of a foreign private issuer· period Oct 24, 2026Document · Index
Oct 20, 20266-KReport of a foreign private issuer· period Oct 20, 2026Document · Index
Oct 1, 20266-KReport of a foreign private issuer· period Oct 1, 2026Document · Index
Sep 24, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Sep 24, 20266-KReport of a foreign private issuer· period Sep 24, 2026Document · Index
Sep 22, 20266-KReport of a foreign private issuer· period Sep 22, 2026Document · Index
Sep 14, 20266-KReport of a foreign private issuer· period Sep 14, 2026Document · Index
Sep 9, 20266-KReport of a foreign private issuer· period Sep 9, 2026Document · Index
Aug 25, 20266-KReport of a foreign private issuer· period Aug 25, 2026Document · Index
Aug 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 31, 20266-KReport of a foreign private issuer· period Jul 30, 2026Document · Index
Jul 29, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jun 8, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Jun 5, 20266-KReport of a foreign private issuer· period Jun 5, 2026Document · Index
Jun 2, 20266-KReport of a foreign private issuer· period Jun 2, 2026Document · Index
Jun 2, 20266-KReport of a foreign private issuer· period Jun 2, 2026Document · Index
May 26, 20266-KReport of a foreign private issuer· period May 26, 2026Document · Index
May 26, 20266-KReport of a foreign private issuer· period May 26, 2026Document · Index
May 22, 20266-KReport of a foreign private issuer· period May 22, 2026Document · Index
May 22, 2026FWPFWPDocument · Index
May 22, 2026424B5424B5Document · Index
May 21, 20266-KReport of a foreign private issuer· period May 21, 2026Document · Index
May 21, 20266-KReport of a foreign private issuer· period May 21, 2026Document · Index
May 21, 20266-KReport of a foreign private issuer· period May 21, 2026Document · Index
May 21, 20266-KReport of a foreign private issuer· period May 20, 2026Document · Index
May 21, 2026FWPFWPDocument · Index
May 21, 2026FWPFWPDocument · Index
May 20, 20266-KReport of a foreign private issuer· period May 20, 2026Document · Index
May 20, 2026424B5424B5Document · Index
May 18, 20266-KReport of a foreign private issuer· period May 17, 2026Document · Index
May 5, 20266-KReport of a foreign private issuer· period May 4, 2026Document · Index
Apr 20, 20266-KReport of a foreign private issuer· period Apr 20, 2026Document · Index
Apr 7, 20266-KReport of a foreign private issuer· period Apr 7, 2026Document · Index
Mar 31, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Mar 31, 20266-KReport of a foreign private issuer· period Mar 31, 2026Document · Index
Mar 30, 20266-KReport of a foreign private issuer· period Mar 30, 2026Document · Index
Mar 26, 20266-KReport of a foreign private issuer· period Mar 26, 2026Document · Index
Mar 25, 20266-KReport of a foreign private issuer· period Mar 25, 2026Document · Index
Mar 12, 20266-KReport of a foreign private issuer· period Mar 12, 2026Document · Index
Feb 25, 20266-KReport of a foreign private issuer· period Feb 25, 2026Document · Index

Insider filing activity

0 Form 4 filings appear in Nanobiotix S.A.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001760854 and XBRL company facts. Nanobiotix S.A. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.